CanSense
About:
CanSense is an accurate, rapid, non-invasive, blood diagnostic for the early detection of cancer.
Website: https://cansenseltd.com/
Twitter/X: CanSenseLtd
Top Investors: Mercia Fund Managers, Development Bank of Wales, Nonacus, National Institute for Health Research
Description:
CanSense is a developer of an inexpensive and scalable blood test intended for early diagnosis of bowel cancer.
Total Funding Amount:
$3.14M
Estimated Revenue Range:
$1M to $10M
Headquarters Location:
Swansea, Swansea, United Kingdom
Founded Date:
2018-01-01
Contact Email:
adam.bryant(AT)cansenseltd.com
Founders:
Number of Employees:
1-10
Last Funding Date:
2023-03-08
IPO Status:
Private
Industries:
© 2025 bioDAO.ai